Travere Therapeutic
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-02-07
- Employees
- 380
- Market Cap
- -
- Website
- http://www.travere.com
- Introduction
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Otsuka eyes early filing of IgAN drug after phase 3 readout
Otsuka's anti-APRIL antibody sibeprenlimab showed significant reduction in uPCR in a phase 3 trial for IgA nephropathy, prompting potential FDA submission. Final results expected in 2026. Competitors include Novartis' zigakibart, Vertex's povetacicept, and Vera's atacicept.
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC investigates Travere Therapeutics, Inc. (NASDAQ: TVTX) after the company paused enrollment in its Phase 3 HARMONY Study due to manufacturing issues. Travere's stock price fell 6.85% following the announcement.
Director Lyons Gary A exercised 40,000 shares at a strike of $10.48 and sold ...
Travere Therapeutics granted 33,500 inducement RSUs to six new employees on Sept. 10, 2024, under Nasdaq Listing Rule 5635(c)(4), vesting over four years.
FDA Approves Sparsentan, With Data Indicating Slowing of Kidney Function Decline in IgA
The FDA has fully approved sparsentan (Filspari; Travere Therapeutics), an oral, non-immunosuppressive medication that significantly slows kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). The approval is based on the PROTECT study, which showed a 1.2 mL/min/1.73m²/year treatment effect over 2 years compared to irbesartan. Sparsentan is well-tolerated and offers a superior option for preserving kidney function.
Related Clinical Trials:
Travere's Filspari safari bags full FDA nod in IgAN; REMS next
Subscribe to BioWorld™ news services.
© Copyright 2024. All Rights Reserved by MedPath